Mesenchymal Stem Cells in Chronic Wounds: The Spectrum from Basic to Advanced Therapy

Advances in Wound Care

Volumn 5, Issue 4, 2016, Pages 149-163

  Otero Viñas, Marta ^a,b   Falanga, Vincent ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GROWTH FACTOR; PENTOXIFYLLINE;

BED; CELL THERAPY; CHRONIC WOUND; COMPRESSION BANDAGE; COMPRESSION STOCKING; COMPRESSION THERAPY; CUSHION; DEBRIDEMENT; ELECTROSTIMULATION; EXTRACORPOREAL LITHOTRIPSY; HUMAN; HYPERBARIC OXYGEN; LOW LEVEL LASER THERAPY; MEDICAL DEVICE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; PHOTOTHERAPY; PRIORITY JOURNAL; REVIEW; SKIN SUBSTITUTE; THROMBOCYTE RICH PLASMA; ULTRASOUND THERAPY; VACUUM ASSISTED CLOSURE; WOUND CLOSURE; WOUND DRESSING; WOUND HEALING;

EID: 84978995661     PISSN: 21621918     EISSN: 21621934     Source Type: Journal    
DOI: 10.1089/wound.2015.0627     Document Type: Review

References (132)

1. Gottrup F. A specialized wound-healing center concept: importance of a multidisciplinary department structure and surgical treatment facilities in the treatment of chronic wounds. Am J Surg 2004; 187:38S-43S.
2. Phillips T, Stanton B, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: financial, social, and psychologic implications. J Am Acad Dermatol 1994;31:49-53.
3. Edwards H, Finlayson K, Courtney M, Graves N, Gibb M, Parker C. Health service pathways for patients with chronic leg ulcers: identifying effective pathways for facilitation of evidence based wound care. BMC Health Serv Res 2014;13:86.
4. Dabiri G, Heiner D, Falanga V. The emerging use of bone marrow-derived mesenchymal stem cells in the treatment of human chronic wounds. Expert Opin Emerg Drugs 2013;18:405-419.
5. Yang W, Dall TM, Halder P, Gallo P, Kowal SL, Hogan PF. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-1046.
6. Hocking AM. Mesenchymal stem cell therapy for cutaneous wounds. Adv Wound Care 2012;1:166-171.
7. Nuschke A. Activity of mesenchymal stem cells in therapies for chronic skin wound healing. Organogenesis 2014;10:29-37.
8. Ankrum J, Karp JM. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med 2010;16:203-209.
9. Ennis WJ, Sui A, Bartholomew A. Stem cells and healing: impact on inflammation. Adv Wound Care 2013;2:369-378.
10. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999;341:738-746.
11. Burnouf T, Goubran HA, Chen T-M, Ou K-L, El-Ekiaby M, Radosevic M. Blood-derived biomaterials and platelet growth factors in regenerative medicine. Blood Rev 2013;27:77-89.
12. Levinson H. A paradigm of fibroblast activation and dermal wound contraction to guide the development of therapies for chronic wounds and pathologic scars. Adv Wound Care 2013;2:149-159.
13. Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 2004;9:283-289.
14. Kim B-C, Kim HT, Park SH, et al. Fibroblasts from chronic wounds show altered TGF-beta-signaling and decreased TGF-beta type II receptor expression. J Cell Physiol 2003;195:331-336.
15. Agren MS, Steenfos HH, Dabelsteen S, Hansen JB, Dabelsteen E. Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent. J Invest Dermatol 1999;112:463-469.
16. Cha J, Falanga V. Stem cells in cutaneous wound healing. Clin Dermatol 2007;25:73-78.
17. Gottrup F, Apelqvist J. Present and new techniques and devices in the treatment of DFU: a critical review of evidence. Diabetes Metab Res Rev 2012;28 Suppl 1:64-71.
18. Panuncialman J, Falanga V. The science of wound bed preparation. Surg Clin North Am 2009;89:611-626.
19. Iwamoto S, Lin X, Ramirez R, et al. Bone marrow cell mobilization by the systemic use of granulocyte colony-stimulating factor (GCSF) improves wound bed preparation. Int J Low Extrem Wounds 2013;12:256-264.
20. Falanga V. Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen 2000;8:347-352.
21. Falanga V, Brem H, Ennis WJ, Wolcott R, Gould LJ, Ayello EA. Maintenance debridement in the treatment of difficult-to-heal chronic wounds. Recommendations of an expert panel. Ostomy Wound Manag 2008(Suppl:2-13):14-15.
22. Sun X, Jiang K, Chen J, et al. A systematic review of maggot debridement therapy for chronically infected wounds and ulcers. Int J Infect Dis 2014;25:32-37.
23. Smith F, Dryburgh N, Donaldson J, Mitchell M. Debridement for surgical wounds (review). Cochrane Database Syst Rev 2013;(9):CD006214.
24. Nelson EA, Bell-Syer SEM. Compression for preventing recurrence of venous ulcers. Cochrane Database Syst Rev 2014;(9):CD002303.
25. Dabiri G, Hammerman S, Carson P, Falanga V. Lowgrade elastic compression regimen for venous leg ulcers - an effective compromise for patients requiring daily dressing changes. Int Wound J. 2013 Nov 25. doi: 10.1111/iwj.12186.
26. Reddy M. Pressure ulcers. Clin Evid (online) 2011:2011;05:1901. www.ncbi.nlm.nih.gov/pmc/ articles/PMC3217823/
27. McInnes E, Sem B, Jc D, Cullum N. Support surfaces for pressure ulcer prevention (review). Cochrane Database Syst Rev 2011;(4):CD001735.
28. Smith ME, Totten A, Hickam DH, et al. Pressure ulcer treatment strategies: a systematic comparative effectiveness review. Ann Intern Med 2013;159:39-50.
29. McInnes E, Dumville JC, Jammali-Blasi A, Bell-Syer EM. Support surfaces for treating pressure ulcers (review). Cochrane Database Syst Rev 2011;(12):CD009490.
30. Chou R, Dana T, Bougatsos C, et al. Pressure ulcer risk assessment and prevention. Ann Intern Med 2013;159:28-38.
31. Fonder MA, Lazarus GS, Cowan DA, Aronson-Cook B, Kohli AR, Mamelak AJ. Treating the chronic wound: a practical approach to the care of nonhealing wounds and wound care dressings. J Am Acad Dermatol 2008;58:185-206.
32. Glass GE, Murphy GF, Esmaeili A, Lai L-M, Nanchahal J. Systematic review of molecular mechanism of action of negative-pressure wound therapy. Br J Surg 2014;101:1627-1636.
33. Sadat U, Chang G, Noorani A,Walsh SR, Hayes PD, Varty K. Efficacy of TNP on lower limb wounds: a meta-analysis. J Wound Care 2008;17:45-48.
34. Llanos S, Danilla S, Barraza C, et al. Effectiveness of negative pressure closure in the integration of split thickness skin grafts: a randomized, double-masked, controlled trial. Ann Surg 2006;244:700-705.
35. Ubbink DT, Westerbos SJ, Evans D, Land L, Vermeulen H. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev 2008;(3):CD001898.
36. Huang C, Leavitt T, Bayer LR, Orgill DP. Effect of negative pressure wound therapy on wound healing. Curr Probl Surg 2014;51:301-331.
37. Webster J, Scuffham P, Stankiewicz M, Chaboyer WP. Negative pressure wound therapy for skin grafts and surgical wounds healing by primary intention (review). Cochrane Database Syst Rev 2014 ;(10):CD009261.
38. Tang JC, MarstonWA, Kirsner RS.Wound healing society (WHS) venous ulcer treatment guidelines: what's new in five years? Wound Repair Regen 2012;20:619-637.
39. Polak A, Franek A, Taradaj J. High-voltage pulsed current electrical stimulation in wound treatment. Adv Wound Care 2014;3:104-117.
40. Kloth LC. Electrical stimulation technologies for wound healing. Adv Wound Care 2014;3:81-90.
41. Petrofsky JS, Lawson D, Berk L, Suh H. Enhanced healing of diabetic foot ulcers using local heat and electrical stimulation for 30 min three times per week. J Diabetes 2010;2:41-46.
42. Aziz Z, Cullum N, Flemming K. Electromagnetic therapy for treating venous leg ulcers (review). Cochrane Database Syst Rev 2013;(2).
43. Thackham JA, Sean McElwain DL, Long RJ. The use of hyperbaric oxygen therapy to treat chronic wounds: a review. Wound Repair Regen 2008;16: 321-330.
44. Thom SR. Oxidative stress is fundamental to hyperbaric oxygen therapy. J Appl Physiol 2009;106: 988-995.
45. Falanga V, Lindholm C, Carson PA, et al. Text atlas of Wound Management, 2nd ed. New York: Informa, 2012.
46. Kranke P, Bennett MH, Martyn-St James M, Schnabel A, Debus SE. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev 2012;4:CD004123.
47. Goldstein LJ. Hyperbaric oxygen for chronic wounds. Dermatol Ther 2013;26:207-214.
48. Stoekenbroek RM, Santema TB, Legemate DA, Ubbink DT, van den Brink A, Koelemay MJ. Hyperbaric oxygen for the treatment of diabetic foot ulcers: a systematic review. Eur J Vasc Endovasc Surg 2014;47:647-655.
49. O'Reilly D, Pasricha A, Campbell K, et al. Hyperbaric oxygen therapy for diabetic ulcers: systematic review and meta-analysis. Int J Technol Assess Health Care 2013;29:269-281.
50. Polak A, Franek A, Blaszczak E, et al. A prospective, randomized, controlled, clinical study to evaluate the efficacy of high-frequency ultrasound in the treatment of stage II and stage III pressure ulcers in geriatric patients. Ostomy Wound Manag 2014;60:16-28.
51. Chaves MEDA, de Araújo AR, Piancastelli ACC, Pinotti M. Effects of low-power light therapy on wound healing: LASER x LED. An Bras Dermatol 2014;89:616-623.
52. Cullum N, Sem B. Therapeutic ultrasound for venous leg ulcers (review). Cochrane Database Syst Rev 2010;(6):CD001180.
53. O'Meara S, Al-Kurdi D, Ologun Y, Ovington LG, Martyn-St James M, Richardson R. Antibiotics and antiseptics for venous leg ulcers (review). Cochrane Database Syst Rev 2014;(1):CD003557.
54. O'Meara S, Al-Kurdi D, Ologun Y, Ovington LG. Antibiotics and antiseptics for venous leg ulcers (review). Cochrane Database Syst Rev 2010;(1): CD003557.
55. Chambers H, Dumville JC, Cullum N. Silver treatments for leg ulcers: a systematic review. Wound Repair Regen 2007;15:165-173.
56. Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Topical silver for preventing wound infection (review). Cochrane Database Syst Rev 2010;(3):CD006478.
57. Stewart JA, McGrane OL, Wedmore IS. Wound care in the wilderness: is there evidence for honey? Wilderness Environ Med 2014;25:103-110.
58. Jull AB, Walker N, Deshpande S. Honey as a topical treatment for wounds (review). Cochrane Database Syst Rev 2013;(2):CD005083.
59. Zbuchea A. Up-to-date use of honey for burns treatment. Ann Burns Fire Disasters 2014;27:22-30. www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4158441&tool=pmcentrez&rendertype=abstract
60. Falanga V, Iwamoto S. Wound repair: Mechanisms and practical considerations. Fitzpatrick's Dermatology in General Medicine. Eds. Wolff K, Goldsmith LS, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. Elsevier. 8th Edition. 2012.
61. O'Meara S, Martyn-st James M. Alginate dressings for venous leg ulcers (review). Cochrane Database Syst Rev 2013;(6):CD010182.
62. S, O'Meara, Martyn-St James M. Foam dressings for venous leg ulcers (review). Cochrane Database Syst Rev 2013;(5):CD009907.
63. Dumville JC, Deshpande S, O'Meara S, Speak K. Foam dressings for healing diabetic foot ulcers (review). Cochrane Database Syst Rev 2013;(6):CD009111.
64. Jc D, Deshpande S, Meara OS, Speak K. Hydrocolloid dressings for healing diabetic foot ulcers (review). Cochrane Database Syst Rev 2013;(8): CD009099.
65. Jc D, Meara OS, Deshpande S, Speak K. Hydrogel dressings for healing diabetic foot ulcers (review). Cochrane Database Syst Rev 2013;(7): CD009101.
66. Mayet N, Choonara YE, Kumar P, et al. A comprehensive review of advanced biopolymeric wound healing systems. J Pharm Sci 2014;103: 2211-2230.
67. Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics 2008;2:1-12.
68. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008; 16:585-601.
69. Buchberger B, Follmann M, Freyer D, Huppertz H, Ehm A, Wasem J. The importance of growth factors for the treatment of chronic wounds in the case of diabetic foot ulcers. GMS Heal Technol Assess 2010;1:6.
70. FDA Approved Drug Products. www.access data.fda.gov/scripts/cder/drugsatfda/ Last accessed date: July 2015.
71. Morimoto N, Yoshimura K, Niimi M, et al. An exploratory clinical trial for combination wound therapy with a novel medical matrix and fibroblast growth factor in patients with chronic skin ulcers: a study protocol. Am J Transl Res 2012;4:52-59.
72. Zhang Y, Wang T, He J, Dong J. Growth factor therapy in patients with partial-thickness burns: a systematic review and meta-analysis. Int Wound J 2014;8:1-13.
73. Falanga V, EaglsteinWH, Bucalo B, KatzMH, Harris B, Carson P. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992;18:604-606.
74. Singla S, Garg R, Kumar A, Gill C. Efficacy of topical application of beta urogastrone (recombinant human epidermal growth factor) inWagner's grade 1 and 2 diabetic foot ulcers: comparative analysis of 50 patients. J Nat Sci Biol Med 2014;5:273-277.
75. Gomez-Villa R, Aguilar-Rebolledo F, Lozano-Platonoff A, et al. Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in mexican patients: a randomized double-blinded controlled trial. Wound Repair Regen 2014;22:497-503.
76. Burnouf T, Goubran HA, Seghatchian J. Multifaceted regenerative lives of expired platelets in the second decade of the 21st century. Transfus Apher Sci 2014;51(2):107-112.
77. Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med 2010;83:1-9.
78. Tsay RC, Vo J, Burke A, Eisig SB, Lu HH, Landesberg R. Differential growth factor retention by platelet-rich plasma composites. J Oral Maxillofac Surg 2005;63:521-528.
79. Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, et al. Autologous platelet-rich plasma for treating chronic wounds. Cochrane Database Syst Rev 2012;17:10.
80. Falanga V, Fujitani RM, Diaz C, et al. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial. Wound Repair Regen 1999;7:208-213.
81. Jull AB, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev 2012;12.
82. Ubbink DT, Santema TB, Stoekenbroek RM. Systemic wound care: a meta-review of cochrane systematic reviews. Surg Technol Int 2014;24:99-111.
83. Lazic T, Falanga V. Bioengineered skin constructs and their use in wound healing. Plast Reconstr Surg 2011;127 Suppl:75S-90S.
84. Koob TJ, Lim JJ, Massee M, et al. Angiogenic properties of dehydrated human amnion/chorion allografts: therapeutic potential for soft tissue repair and regeneration. Vasc Cell 2014;6:10.
85. Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen 1999;7:201-207.
86. Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging 2007;2:93-98.
87. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers. Diabetes Care 2001;24:290-295.
88. Falanga V, Isaacs C, Paquette D, et al. Wounding of bioengineered skin: cellular and molecular aspects after injury. J Invest Dermatol 2002;119:653-660.
89. Jones JE, Nelson EA, Al-Hity A. Skin grafting for venous leg ulcers (review). Cochrane Database Syst Rev 2013;(1):CD001737.
90. Capo JT, Kokko KP, Rizzo M, et al. The use of skin substitutes in the treatment of the hand and upper extremity. Hand (N Y) 2014;9:156-165.
91. Wagers AJ, Weissman IL. Plasticity of adult stem cells. Cell 2004;116:639-648.
92. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872.
93. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917-1920.
94. International clinical trials involving stem cells are collected. https://clinicaltrials.gov.
95. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006;8: 315-317.
96. Satija NK, Singh VK, Verma YK, et al. Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med 2013;13:4385-4402.
97. Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. Aging of mesenchymal stem cell in vitro. BMC Cell Biol 2006;7:14.
98. Wagner W, Horn P, Castoldi M, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 2008;3:e2213.
99. Cheng NC, Chen SY, Li JR, Young TH. Short-term spheroid formation enhances the regenerative capacity of adipose-derived stem cells by promoting stemness, angiogenesis, and chemotaxis. Stem Cells Transl Med 2013;2:584-594.
100. Parmar N, Ahmadi R, Day RM. A novel method for differentiation of human mesenchymal stem cells into smooth muscle-like cells on clinically deliverable thermally induced phase separation microspheres. Tissue Eng Part C Methods 2014;201:404-412.
101. Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol 2006;24:150-154.
102. Nie C, Yang D, Morris SF. Local delivery of adiposederived stem cells via acellular dermal matrix as a scaffold: a new promising strategy to accelerate wound healing. Med Hypotheses 2009;72:679-682.
103. Sasaki M, Abe R, Fujita Y, Ando S, Inokuma D, Shimizu H. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol 2008;180:2581-2587.
104. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007;25:2648-2659.
105. Badiavas E, Falanga V. Treatment of chronic wounds with bone marrow-derived cells. Arch Dermatol 2003;139:510-516.
106. Falanga V, Iwamoto S, Chartier M, et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 2007;13:1299-1312.
107. Javazon EH, Keswani SG, Badillo AT, et al. Enhanced epithelial gap closure and increased angiogenesis in wounds of diabetic mice treated with adult murine bonemarrowstromal progenitor cells. Wound Repair Regen 2007;15:350-359.
108. Kim J-W, Lee J-H, Lyoo YS, Jung D-I, Park H-M. The effects of topical mesenchymal stem cell transplantation in canine experimental cutaneous wounds. Vet Dermatol 2013;24:242-e53.
109. Dash NR, Dash SN, Routray P, Mohapatra S, Mohapatra PC. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res 2009;12:359-366.
110. Jain P, Perakath B, Jesudason MR, Nayak S. The effect of autologous bone marrow-derived cells on healing chronic lower extremity wounds: results of arandomized controlled study. Ostomy Wound Manag 2011;57:38-44.
111. Wikramanayake TC, Stojadinovic O, Tomic-Canic M. Epidermal differentiation in barrier maintenance and wound healing. Adv Wound Care 2014;3:272-280.
112. Rustad KC, Wong VW, Sorkin M, et al. Enhancement of mesenchymal stem cell angiogenic capacity and stemness by a biomimetic hydrogel scaffold. Biomaterials 2012;33:80-90.
113. Lam MT, Nauta A, Meyer NP, Wu JC, Longaker MT. Effective delivery of stem cells using an extracellular matrix patch results in increased cell survival and proliferation and reduced scarring in skin wound healing. Tissue Eng Part A 2013;19:738-747.
114. Matthay MA, Goolaerts A, Howard JP, Lee JW. Mesenchymal stem cells for acute lung injury: preclinical evidence. Crit Care Med 2010;38(Suppl 10):1-9.
115. Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 2011;9:12.
116. Kokai LE, Marra K, Rubin JP. Adipose stem cells: biology and clinical applications for tissue repair and regeneration. Transl Res 2014;163:399-408.
117. Wu Y, Huang S, Enhe J, et al. Bone marrow-derived mesenchymal stem cell attenuates skin fibrosis development in mice. Int Wound J 2013;11:701-710.
118. Li H, Fu X. Mechanisms of action of mesenchymal stem cells in cutaneous wound repair and regeneration. Cell Tissue Res 2012;348:371-377.
119. Hocking AM, Gibran NS. Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. Exp Cell Res 2010;316:2213-2219.
120. Chen L, Tredget EE, Wu PYG, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008;3:e1886.
121. Kim WS, Park BS, Sung JH, et al. Wound healing effect of adipose-derived stem cells: a critical role of secretory factors on human dermal fibroblasts. J Dermatol Sci 2007;48:15-24.
122. Wang CY, Yang HB, Hsu HS, et al. Mesenchymal stem cell-conditioned medium facilitates angiogenesis and fracture healing in diabetic rats. J Tissue Eng Regen Med 2012;6:559-569.
123. Hassan WU, Greiser U, Wang W. Role of adipose-derived stem cells in wound healing. Wound Repair Regen 2014;22:313-325.
124. Huang SP, Hsu CC, Chang SC, et al. Adiposederived stem cells seeded on acellular dermal matrix grafts enhance wound healing in a murine model of a full-thickness defect. Ann Plast Surg 2012;69:656-662.
125. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012;7: e47559.
126. Rubio D, Garcia-Castro J, Martín MC, et al. Spontaneous human adult stem cell transformation. Cancer Res 2005;65:3035-3039.
127. Zhang T, Lee YW, Rui YF, Cheng TY, Jiang XH, Li G. Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell Res Ther 2013;4:70.
128. Phinney DG. Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem 2012;113:2806-2812.
129. Tian H, Lu Y, Shah SP, Hong S. 14S,21Rdihydroxydocosahexaenoic acid remedies impaired healing and mesenchymal stem cell functions in diabetic wounds. J Biol Chem 2011;286:4443-4453.
130. Yufit T, Carson P, Falanga V. Topical delivery of cultured stem cells to human non-healing wounds: gmp facility development in an academic setting and fda requirements for an ind for human testing. Curr Drug Deliv 2014;11:572-581.
131. Sipp D, Turner L. Stem cells. U.S. regulation of stem cells as medical products. Science 2012;338:1296-1297.
132. Lin X, Kwak T, Fiore D, et al. An in vitro priming step increases the expression of numerous epidermal growth and migration mediators in a tissueengineering construct. J Tissue Eng Regen Med 2014 [Epub ahead of print]; DOI: 10.1002/term.1967.